Stock Movers Enagas Soars, AstraZeneca Gains, Pernod Ricard Rises
Mar 27, 2026
Tiwa Adebayo, Bloomberg equities reporter who covers European markets on the ground. She breaks down Enagas's surge after a regulator's draft proposal. She covers AstraZeneca’s COPD trial news and its market implications. She discusses Pernod Ricard’s reported talks about Brown‑Forman and potential U.S. market impact.
AI Snips
Chapters
Transcript
Episode notes
Enagas Gains From Surprise Regulator Boost
- Enagas stock surged after Spain's CNMC draft offered unexpectedly positive terms for gas firms.
- JPMorgan estimated Enagas could see €650m–€750m of incremental revenue in the first year under the proposals.
AstraZeneca COPD Trial Shows Market Potential
- AstraZeneca's experimental COPD drug showed statistically significant reductions in flare-ups across two late-stage trials.
- Analysts project potential sales of about $866m annually by 2032, though full data will be presented at a medical meeting.
Wait For Full Data Before Pricing Drug Success
- Treat early trial press releases with caution until full data is presented and scrutinized.
- Bloomberg Intelligence warned about limited detail in AstraZeneca's statement and awaits forthcoming presentation.